JERUSALEM, Sept 7 (Reuters) – Shares of Israeli biotech firm Protalix reversed gains on Sunday after the company’s chief executive threw cold water on a news report that its technology could be used to develop a version of the Ebola experimental drug ZMapp.

Source: http://feeds.reuters.com/~r/reuters/AfricaNigeriaNews/~3/V7I14lLSOOk/idAFL5N0R80P220140907